Gene Polymorphisms Affecting the Pharmacokinetics and Pharmacodynamics of Donepezil Efficacy
Donepezil (DNP) is the first-line drug used for Alzheimer's disease (AD). However, the therapeutic response rate of patients to DNP varies from 20 to 60%. The main reason for the large differences in the clinical efficacy of DNP therapy is genetic factors, some of which affect pharmacokinetics...
Saved in:
Main Authors: | Jin Lu (Author), Xiuzhe Wang (Author), Lili Wan (Author), Jianliang Fu (Author), Yan Huo (Author), Yuwu Zhao (Author), Cheng Guo (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease
by: Jin Lu, et al.
Published: (2015) -
Transporter and metabolizer gene polymorphisms affect fluoroquinolone pharmacokinetic parameters
by: Nurul Annisa, et al.
Published: (2022) -
Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology
by: Siyu Liu, et al.
Published: (2024) -
Pharmacokinetic Evaluation of a Novel Donepezil-Loaded Dissolving Microneedle Patch in Rats
by: Naveed Ur Rehman, et al.
Published: (2021) -
Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma
by: Hironao Okubo, et al.
Published: (2022)